Figures
Abstract
Background
High-sensitivity cardiac troponins (hs-cTn) are the preferred biomarkers to detect myocardial injury, making them promising risk-stratifying tools for patients with symptoms of chest pain. However, circulating hs-cTn are also elevated in other conditions like renal dysfunction, complicating appropriate interpretation of low-level hs-cTn concentrations.
Methods
A cross-sectional analysis was performed in 1864 patients with symptoms of chest discomfort from the cardiology outpatient department who underwent cardiac computed tomographic angiography (CCTA). Serum samples were analyzed using hs-cTnT and hs-cTnI assays. Renal function was measured by the estimated glomerular filtration rate (eGFR), established from serum creatinine and cystatin C. On follow-up, the incidence of adverse events was assessed.
Results
Median hs-cTnT and hs-cTnI concentrations were 7.2(5.8–9.2) ng/L and 2.6(1.8–4.1) ng/L, respectively. Multivariable regression analysis revealed that both assay results were more strongly associated with eGFR (hs-cTnT:stβ:-0.290;hs-cTnI:stβ:-0.222) than with cardiac imaging parameters, such as coronary calcium score, CCTA plaque severity score and left ventricular mass (all p<0.01). Furthermore, survival analysis indicated lower relative risks in patients with normal compared to reduced renal function for hs-cTnT [HR(95%CI), 1.02(1.00–1.03) compared to 1.07(1.05–1.09)] and hs-cTnI [1.01(1.00–1.01) compared to 1.02(1.01–1.02)] (all p<0.001).
Conclusion
In patients with chest discomfort, we identified an independent influence of renal function on hs-cTn concentrations besides CAD, that affected the association of hs-cTn concentrations with adverse events. Estimating renal function is therefore warranted when interpreting baseline hs-cTn concentrations.
Citation: Cardinaels EPM, Altintas S, Versteylen MO, Joosen IA, Jellema L-JC, Wildberger JE, et al. (2016) High-Sensitivity Cardiac Troponin Concentrations in Patients with Chest Discomfort: Is It the Heart or the Kidneys As Well? PLoS ONE 11(4): e0153300. https://doi.org/10.1371/journal.pone.0153300
Editor: Tobias Eckle, University of Colorado Denver, UNITED STATES
Received: June 19, 2015; Accepted: March 11, 2016; Published: April 20, 2016
Copyright: © 2016 Cardinaels et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: This work was supported by a research grant from Stichting De Weijerhorst (http://www.deweijerhorst.nl/weijerhorst/home) to M.P v.D-V. The hs-cTnI kits were kindly provided by Abbott Diagnostics. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The hs-cTnI kits were provided by Abbott Diagnostics. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Introduction
Identifying chest pain patients at risk for cardiovascular events remains an ongoing challenge [1]. A promising and cost-effective way to identify those “vulnerable” patients is the use of cardiac troponins [2,3]. Because of their unique cardiospecificity, cardiac troponins T (cTnT) or I (cTnI) are considered the preferred biochemical markers to detect myocardial injury and to diagnose acute myocardial infarction (AMI) in particular [4]. Since the introduction of high-sensitivity cardiac troponin (hs-cTn) assays, more accurate detection of low levels of circulating cardiac troponins became feasible [5], which significantly improved the diagnostic performance in patients with acute cardiac risk [6]. Even below the diagnostic cut-off, hs-cTn concentrations turned out to have an important prognostic value for acute cardiovascular events [7–9]. Moreover, in patients with stable coronary artery disease (CAD) low concentrations of hs-cTnT have been associated to the extent of CAD [2] and coronary plaque phenotypes that are more prone to rupture [3].
Unfortunately, the shift to more sensitive assays is accompanied by a reduction in specificity, as circulating hs-cTn levels are elevated in many other conditions besides AMI [7,10]. Renal dysfunction is one of those conditions in which elevated cardiac troponin concentrations are commonly detected [11,12]. Recently it was shown in chronic kidney disease (CKD) patients that elevated hs-cTn concentrations are indeed associated with reduced renal function [13]. Therefore, the interpretation of baseline hs-cTn values in the individual patient is complicated not only by cardiac disease [14–16] but also renal dysfunction.
As of yet it is unknown to what extent renal function contributes to higher cardiac troponin concentrations in stable patients with chest discomfort, in whom circulating hs-cTnT concentrations are mainly attributed to the presence and severity of atherosclerotic plaques [2,3] or echocardiographic abnormalities [17–19]. In-depth understanding in which way renal function affects hs-cTnT and hs-cTnI concentrations is of utmost importance for the use of hs-cTn values in clinical practice.
This study is the first to evaluate the impact of a decreased renal function on both hs-cTnT and hs-cTnI concentrations relative to the presence of cardiovascular disease in patients who visited the cardiology outpatient department with symptoms of chest discomfort. Moreover, the renal influence on the association of hs-cTn with the incidence of adverse events is investigated.
Materials and Methods
Study cohort
This study was approved by the Institutional Review Board (IRB) and Ethics Committee at the Maastricht University. Involved data were collected on a routine basis within the Maastricht Biomarker CT study (ClinicalTrials.gov NCT01671930, MEC 08-4-057) and data were analyzed anonymously in accordance with IRB guidelines. The study complies with the ethical principles of the Helsinki Declaration.
We analyzed a cohort of 1864 consecutive patients who were enrolled in the Maastricht Biomarker CT Study. This cohort is comprised of patients from the cardiology outpatient department presenting with (a)typical chest pain with a low-to-intermediate pretest probability who were referred for CCTA for the evaluation of stable coronary artery disease (CAD), in accordance with the current guidelines [1,20]. Included were patients of whom serum was collected prior to CCTA and excluded were patients with a previous history or diagnosis of ACS at the time of CCTA and patients with severe renal dysfunction or on dialysis (due to application of contrast fluids) (Fig 1).
Previous results from the Maastricht Biomarker CT Study and additional specifications of this population have been published elsewhere [2,21,22].
Biochemical analysis
Serum samples were collected immediately before CCTA, processed within 2 hours and directly stored at -80°C until analysis. Total cholesterol, triglycerides, high-density and low-density lipoprotein concentrations were measured as previously described [2]. Serum creatinine, cystatin C and cTnT concentrations were measured on the Cobas 6000 analyzer (Roche Diagnostics) in a fresh aliquot. Creatinine concentrations were assessed using the enzymatic method (Roche). Cystatin C was measured using a new particle-enhanced turbidimetric assay (Gentian AS), that was standardized against the certified ERM-DA471/IFCC cystatin C reference material [23]. The glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration equations [24] using serum creatinine and cystatin C concentrations. cTnT concentrations were determined using the high-sensitivity cTnT assay (Roche; lotnumber 167650), with a 99th percentile upper reference limit of 14 ng/L and a 10% coefficient of variation (CV) cut-off at 13 ng/L. Gender-specific cutoffs were reported at 14.5 ng/L and 10 ng/L for males and females, respectively [5]. cTnI measurements were performed on the ARCHITECT i2000SR platform using the precommercial ARCHITECT STAT high-sensitivity troponin I (hs-cTnI) assay (Abbott Laboratories). According to the manufacturer, a 10% CV was reached at 4.7 ng/L and the 99th percentile cut-off concentration at 26.2 ng/L for the overall population. Gender-specific cut-offs at 34.2 ng/L and 15.6 ng/L were also defined for males and females, respectively. In duplo measurements of multiple serum samples (>20) ranging between 7–12 ng/L in hs-cTnT-concentration and 3–4 ng/L in hs-cTnI-concentration, were measured with CVs of 3% and 9% respectively.
Cardiac computed tomographic angiography
CCTAs were performed from December 2007 through December 2012 and analyzed as previously described [21]. In brief, CCTA were analyzed by two experts who were blinded from hs-cTn results. The coronary calcium score (CCS) was quantified by the Agatston method [25] and luminal plaque severity as assessed by CCTA was scored as no, mild (<50% stenosis), moderate (50–70% stenosis) and severe (>70% stenosis) CAD.
Echocardiography
Echocardiography was performed in a subset of 549 patients (31%) within a period of 3 months from the CCTA scan by an expert echocardiographist, who was blinded for hs-cTn concentrations. Transthoracic images of the left ventricle (LV) were acquired to assess morphology, function and mass (Philips IE 33, Philips Medical Systems). LV function and -mass were calculated by off-line image analysis using Xcelera software package (Philips Medical Systems), according to current ESC/AHA guidelines [26]. Left ventricular hypertrophy was defined as an LVmass >95 g/m2 in females or LVmass >115 g/m² in males [27].
Study endpoints
Electronic patient records were monitored for the occurrence of adverse events by two reviewers. Survival time was defined as the period from date of CCTA to date of the first event or the end of follow-up (June 2013). The composite study endpoints were defined in advance as mortality and major adverse cardiovascular events, encompassing acute coronary syndromes including AMI and unstable angina requiring hospitalization; and late coronary revascularization (>90 days after CCTA), such as percutaneous coronary interventions and coronary artery bypass grafting [22]. We cannot completely rule out that CCTA outcomes presented in this study were used in the decision to perform coronary revascularization in these patients during follow up. However, we corrected for this bias by excluding the procedures that were performed within 90 days after CCTA. No records could be retrieved of 175 subjects, therefore 1689 patients (91%) of the total cohort were included for follow-up analysis.
Statistical analysis
Differences in baseline characteristics across hs-cTn categories were performed using the T-test for continuous variables with a normal distribution, Mann-Whitney U-test for non-normal distributed continuous variables and Chi square test for categorical variables. Data are presented as proportions, means ± standard deviations, and data with a non-normal distribution are given as the median (interquartile range, IQR). Pearson R correlation factors were calculated with the natural logarithm (Ln) of hs-cTnT and hs-cTnI, to normalize their skewed distribution. To assess the independent association of renal and cardiovascular parameters with hs-cTn concentrations, linear regression analyses were performed with either Ln(hs-cTnT) or Ln(hs-cTnI) as the dependent variable. Only the cardiovascular risk factors that were significantly associated to higher hs-cTnT concentrations were entered as independent variables into the multivariable model. R² was calculated to measure the performance of the model, and the R² change to address the additive effect of eGFR to the model. Interaction terms between eGFR and either CCTA and echocardiography-parameters were not statistically significant (p>0.05). Univariable and multivariable cox-proportional hazards models were performed to investigate the relationship of hs-cTn and the risk on adverse events during follow-up. Results are presented as hazard ratio (HR) and 95% confidence intervals (95%CI). None of the attending clinicians had access to the hs-cTnT and hs-cTnI concentrations, measured at the time of CCTA, for the diagnosis of outcome events. Statistical analysis was performed with SPSS 20.0 (SPSS). Two sided p-values of ≤0.05 were considered statistically significant.
Results
Distribution and determinants of hs-cTnT and hs-cTnI
Median (IQR) hs-cTn concentrations in this cohort were 7.2 (5.8–9.2) ng/L for hs-cTnT and 2.6 (1.8–4.1) ng/L for hs-cTnI. Of all patients, 6.6% (n = 123) were above the cutoff of hs-cTnT (14 ng/L) and 2.1% (n = 30) above the cutoff of hs-cTnI (26.2 ng/L). Using simple linear regression, we found a strong correlation between both hs-cTn concentrations (Pearson R 0.635, p<0.001). However, the biological equivalent for hs-cTnI to a hs-cTnT concentration of 14 ng/L was found to be at 6.4 ng/L (S1 Fig), which is in line with recently published results [28]. The majority of all patients (72%) had a normal renal function (eGFR>90 mL/min/1.73m²) and 98% had an eGFR above 60 mL/min/1.73m². The baseline characteristics are presented in Table 1 and illustrate that increasing quartiles of hs-cTnT and hs-cTnI were highly associated with traditional cardiovascular risk factors such as advancing age, male sex and increased blood pressure.
Independent association of cardiovascular disease and renal function with hs-cTn concentrations
Univariable regression analysis demonstrated that hs-cTn concentrations are significantly associated with eGFR (hs-cTnT: R:-0.396; hs-cTnI: R:-0.251; S2 Fig), regardless of the algorithm that is used to estimate GFR (data not shown). Also, both hs-cTnT and hs-cTnI concentrations are significantly correlated with CCS (hs-cTnT: R:0.279; hs-cTnI: R:0.213) and CCTA plaque severity (hs-cTnT: R:0.307; hs-cTnI, R:0.230) (Table 2, all p<0.001).
As displayed by Fig 2, when adding renal and CT parameters as explanatory variables for hs-cTn concentrations in a multivariable regression model, both eGFR, CCS as CCTA plaque severity were identified as independent predictors (Table 2, unadjusted multivariable model).
Median hs-cTnT (A) and hs-cTnI (B) concentrations according to estimated GFR categories and coronary calcium score or CCTA plaque severity. AS, agatston score.
Similar standardized βeGFR (stβeGFR) coefficients were observed in the univariable versus unadjusted multivariable models, indicating that CT parameters and eGFR hardly influenced each other when predicting hs-cTnT or hs-cTnI concentrations (Table 2).
After adjustment for traditional cardiovascular risk factors, eGFR, CCS and CCTA plaque severity score remained significantly associated with hs-cTn concentrations (Table 2, adjusted multivariable model 1 and 2, respectively). Also here, stβeGFR, stβCCS and stβCCTA values remain unchanged (Table 2, adjusted multivariable models 1–3).The independent contribution of eGFR to the prediction of hs-cTnT and hs-cTnI concentrations was also demonstrated by significant and identical R² changes (hs-cTnT: 0.056, hs-cTnI: 0.030; all p<0.001) when adding eGFR either to the baseline model or to adjusted multivariable model 2.
Furthermore, the association of eGFR with hs-cTn concentrations remained equally strong when subdividing this cohort into patients with no (hs-cTnT:stβeGFR:-0.295; hs-cTnI:stβeGFR:-0.228), mild (hs-cTnT:stβeGFR:-0.290; hs-cTnI:stβeGFR:-0.176) and moderate-to-severe CAD (hs-cTnT:stβeGFR:-0.293;hs-cTnI: stβeGFR:-0.249) (all p<0.001), confirming the independent influence of eGFR on hs-cTn concentrations beyond CAD severity (S1 Table). This finding was visible but less apparent for hs-cTnI than for hs-cTnT.
In a subgroup of this cohort, also echocardiographic parameters were included as explanatory variables for hs-cTn concentrations. Univariably, hs-cTnT and hs-cTnI were significantly associated with the echocardiographic measures LVEF (hs-cTnT: R:-0.151, p = 0.001; hs-cTnI, R:-0.142, p = 0.002) and LVmass (hs-cTnT: R:0.253; hs-cTnI: R:0.309; p<0.001) (S2 Table). In line with previous results, stβeGFR coefficients were only influenced by the confounding effects of traditional cardiovascular risk factors and not by any of the measured CT parameters or echocardiographic parameters (Table 3).
Almost identical standardized β values (stβ) for eGFR were observed when comparing adjusted multivariable models 1, 3 and 5, indicating the independent influence of eGFR on hs-cTn concentrations beyond echocardiographic parameters.
In total, 30% and 19% of hs-cTnT and hs-cTnI variation, respectively, could be explained by the most important independent predictors: eGFR, CCS, LVmass, age and male sex (Table 3).
Hs-cTn remain significant and comparable prognostic markers for adverse events
Over a mean follow-up period of 2.9±1.5 years, 68 adverse events (4.0%) were observed, encompassing 33 patients who underwent late revascularization, 18 patients that suffered from a non-fatal acute coronary syndrome and 17 patients who died. From all traditional risk factors, only age, smoking and total cholesterol were significantly different in the event versus non-event group (S3 Table).
As depicted in Table 4, univariable Cox regression analysis showed that the incidence of adverse events was significantly associated with hs-cTnT and hs-cTnI. Both hs-cTn results remained highly significant predictors for adverse events when adjusted for significant traditional risk factors and even CCS (Table 4) and CAD-severity (S4 Table). Overall, patients with elevated hs-cTnT (>14 ng/L) and hs-cTnI (>26.2 ng/L) concentrations were respectively 3 and 8 times more at risk for adverse events on follow-up.
However, renal function significantly affected the association between hs-cTnT and hs-cTnI with adverse events (p-value interaction term, <0.001 and 0.007, respectively). Higher hs-cTnT concentrations showed lower survival rates for adverse cardiac events when eGFR was <90 mL/min/1.73m² in comparison when eGFR was ≥90 mL/min/1.73m² (as illustrated by the Kaplan-Meier curves in S3 Fig). Consequently, in patients with eGFR <90mL/min/1.73m², a 1 ng/L-rise in hs-cTnT and hs-cTnI resulted in an increased relative risk of 7.1% and 1.5% respectively. However this increase in relative risk was 4 to 2 times less for hs-cTnT (2%) and hs-cTnI (0.6%) in patients with normal renal function (eGFR ≥90 mL/min/1.73m²).
Discussion
The present study provides new insights into the interpretation of hs-cTn concentrations in patients with chest discomfort, identifying not only cardiac parameters but also renal function as independent and strong contributors to circulating hs-cTn concentrations. In fact, eGFR exhibited limited confounding effects on the association between hs-cTn and stable CAD but did interfere with the association between hs-cTn and the risk on adverse events, such as mortality and AMI.
Influence of renal function on hs-cTnT and hs-cTnI concentrations
In patients with chest discomfort, we found that hs-cTnT and hs-cTnI were strongly correlated with eGFR. Also in patients with noncardiac cause of chest pain, eGFR was found to be next to age an important determinant for hs-cTnT concentrations [29]. Even within normal eGFR boundaries, our results clearly demonstrate that a decreased renal clearance affects is associated with hs-cTn concentrations. Although differences were small, hs-cTnT was more strongly correlated with eGFR than hs-cTnI, which was also reported in subjects with moderate-to-severe CKD [13,30]. In addition, the association between hs-cTnT concentrations and eGFR were stronger than any known associations between hs-cTnT and cardiac parameters, such as coronary plaque severity [2,3,31] or left ventricular structure [16,18,32]. Interestingly, this is in contrast to hs-cTnI, in which the association with LVmass was greater than with eGFR. For clinical decision making, hs-cTnT and hs-cTnI assays are currently used interchangeably from each other. However, these findings suggest that hs-cTnT could be more susceptible to changes in renal clearance than hs-cTnI. Future research should further examine these differences between hs-cTnT and hs-cTnI.
Renal and cardiac parameters are two independent contributors to hs-cTn
Importantly, we demonstrate for the first time that the extent of stable CAD and echocardiographic characteristics of the left ventricle did not interfere with the magnitude of the association between eGFR and hs-cTn concentrations. As a consequence, in non-acute patients with a normal to mildly impaired kidney function, decreases in renal function and the extent of stable CAD can be considered as two contributors of hs-cTn accumulation. Further research is necessary to examine the association of hs-cTn with renal function relative to cardiovascular disease in populations such as acute chest pain and chronic heart failure patients.
The significant association between eGFR and hs-cTn concentrations, independent from cardiac pathologies, is in line with the observation that cTnT and cTnI are cleared by the kidneys [33,34]. However, we cannot exclude that a decreased renal function may exert additional myocardial stress that is not identified by cardiac imaging, leading to subsequent cardiac troponin release. We were able to explain up to 30% of the variation in hs-cTn concentrations, and therefore unknown or undetected pathologies to the myocardium can also result in cTn release that was not taken into account.
Furthermore, these findings provide an explanation for the reduced diagnostic performance of hs-cTn seen in AMI patients with lower renal function in comparison to those with normal renal function [35,36]. Therefore, when acquiring the diagnostic hs-cTn cutoffs from reference populations (99th upper reference limit), it is of equal importance to screen for renal as for cardiac health.
Significant influence of renal function on the prognostic value of hs-cTn
In this study, we found that serum hs-cTnT as well as hs-cTnI were significant prognostic markers for the prediction of adverse events, independent from other established risk predictors, such as CCS. These results therefore indicate that both hs-cTn are not only useful risk stratifyers in patients at serious risk for adverse events [8,9,32,37], but also contribute significantly in a low-risk stable CAD population.
When adjusted for decreased renal function, hs-cTnT and hs-cTnI remain significant prognostic markers for adverse events, as found in other study populations [38,39], although renal function significantly modified this association. Therefore, increases in hs-cTnT and hs-cTnI indicate respectively 4 and 2 times more risk in patients with reduced renal function compared to patients with normal renal function. The rationale behind these results could be in line with previous findings that patients with decreased renal function are more at risk for developing events [40,41]. Moreover, the attenuation in hazard ratios was more pronounced for hs-cTnT than hs-cTnI, and correspond to our previous observation that hs-cTnT was more associated with renal function than hs-cTnI. Nonetheless, in the patients with both reduced and normal eGFR, hs-cTnT and hs-cTnI concentrations hold an important prognostic value besides important risk predictors such as CCS, age and smoking. Prospective studies must establish whether baseline hs-cTn concentrations should therefore be accompanied by GFR-assessment.
Conclusion
In conclusion, we identified in patients with symptoms of chest discomfort that renal function has a moderate and independent influence on circulating hs-cTnT and hs-cTnI concentrations. Moreover, renal function significantly affected the association of hs-cTnT and hs-cTnI with adverse events. Therefore, our results seriously question whether baseline hs-cTn concentrations should be reported without the access to an eGFR.
Supporting Information
S1 Fig. Scatterplots and simple linear regression of the association between Ln(hs-cTnT) and Ln(hs-cTnI).
The regression line follows the linear function y = 1.37 x—1.75.
https://doi.org/10.1371/journal.pone.0153300.s001
(DOCX)
S2 Fig.
Scatterplots of the association of eGFR with Ln (hs-cTnT) (A) and Ln (hs-cTnI) (B).
https://doi.org/10.1371/journal.pone.0153300.s002
(DOCX)
S3 Fig. Kaplan-Meier curves for the estimation of risk on all-cause mortality according to different eGFR and hs-cTnT or hs-cTnI categories.
hs-cTnThigh indicates hs-cTnT > 4th quartile (= 9.2 ng/L); hs-cTnTlow, hs-cTnT <4th quartile; hs-cTnIhigh, hs-cTnI >4th quartile (4.1 ng/L); hs-cTnIlow, hs-cTnI <4th quartile; eGFRnormal indicates eGFR >90 mL/min/1.73m2; eGFRreduced eGFR, <90 mL/min/1.73 m2.
https://doi.org/10.1371/journal.pone.0153300.s003
(DOCX)
S1 Table. Association of hs-cTnT or hs-cTnI concentrations with (A) eGFR in patients without CAD (n = 756), mild (n = 667) and moderate-to-severe CAD (n = 441) and (B) CCS in patients with eGFR < 90 mL/min/1.73m² (n = 524) and eGFR > = 90 mL/min/1.73m² (n = 1340), indicating almost identical unstandardized and standardized β values for eGFR (stβeGFR) and CCS (stβCCS) across these different categories.
*, indicates Stβ obtained from the regression model containing also the variables age, gender, BMI, Family history, Systolic BP, diastolic BP and total cholesterol; †, p<0.001.
https://doi.org/10.1371/journal.pone.0153300.s004
(DOCX)
S2 Table. Baseline characteristics of subpopulation (N = 549/1876 patients) in which echocardiography was performed, by median hs-cTnT and hs-cTnI concentrations.
https://doi.org/10.1371/journal.pone.0153300.s005
(DOCX)
S3 Table. Differences in baseline characteristics between cardiovascular event and event-free group.
https://doi.org/10.1371/journal.pone.0153300.s006
(DOCX)
S4 Table. Cox proportional regression analysis for the association of hs-cTnT and hs-cTnI with adverse events in all patients or when stratified for eGFR ≥or <90mL/min/1.73m².
All models were adjusted to age, gender, smoking, total cholesterol and CAD-severity score.
https://doi.org/10.1371/journal.pone.0153300.s007
(DOCX)
Acknowledgments
We sincerely thank Abbott Diagnostics for providing the hs-cTnI kits. The authors also acknowledge the contribution of dr. L. Hofstra to the CT study and the laboratory assistance of V.W.V.C. Kleijnen. This work was supported by a research grant from Stichting De Weijerhorst to M.P v.D-V.
Author Contributions
Conceived and designed the experiments: EC BK AM. Performed the experiments: EC SA IJ MV. Analyzed the data: EC BK AM. Contributed reagents/materials/analysis tools: LJ JW MD HC. Wrote the paper: EC SA MV IJ LJ JW MD HC OB MvDV BK AM.
References
- 1. ESC Task Force Members. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949–3003. pmid:23996286
- 2. Laufer EM, Mingels AM, Winkens MH, Joosen IA, Schellings MW, Leiner T, et al. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010; 30: 1269–1275. pmid:20299689
- 3. Korosoglou G, Lehrke S, Mueller D, Hosch W, Kauczor HU, Humpert PM, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011; 97: 823–831. pmid:20884786
- 4. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–2035. pmid:22923432
- 5. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 254–261. pmid:19959623
- 6. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858–867. pmid:19710484
- 7. Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. Arch Intern Med 2007; 167: 276–281. pmid:17296884
- 8. Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 2010; 55: 2118–2124. pmid:20447535
- 9. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltytė Benth J, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013; 61: 1240–1249. pmid:23414791
- 10. Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol 2013; 10: 623–634. pmid:23979214
- 11. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353–359. pmid:12865376
- 12. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002; 40: 2065–2071. pmid:12505215
- 13. deFilippi C, Seliger SL, Kelley W, Duh SH, Hise M, Christenson RH, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 2012. 58: 1342–1351. pmid:22791885
- 14. Bansal N, Hyre Anderson A, Yang W, Christenson RH, deFilippi CR, Deo R, et al. High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2015; 26:946–956 pmid:25278510
- 15. Dubin RF, Li Y, He J, Jaar BG, Kallem R, Lash JP, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol 2013; 14: 229. pmid:24148285
- 16. Mishra RK, Li Y, DeFilippi C, Fischer MJ, Yang W, Keane M, et al. Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis 2013; 61: 701–709. pmid:23291148
- 17. Chin CW, Shah AS, McAllister DA, Joanna Cowell S, Alam S, Langrish JP, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J.2014; 35:2312–2321. pmid:24829362
- 18. Røsjø H, Andreassen J, Edvardsen T, Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol 2011; 108: 88–91. pmid:21529731
- 19. Beatty AL, Ku IA, Christenson RH, DeFilippi CR, Schiller NB, Whooley MA. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med 2013; 173: 763–769. pmid:23568589
- 20. Hermann LK, Weingart SD, Yoon YM, Genes NG, Nelson BP, Shearer PL, et al. Comparison of frequency of inducible myocardial ischemia in patients presenting to emergency department with typical versus atypical or nonanginal chest pain. Am J Cardiol 105: 1561–1564. pmid:20494662
- 21. Joosen IA, Schiphof F, Versteylen MO, Laufer EM, Winkens MH, Nelemans PJ, et al. Relation between mild to moderate chronic kidney disease and coronary artery disease determined with coronary CT angiography. PLoS One 2012; 7: e47267. pmid:23071773
- 22. Mingels AM, Joosen IA, Versteylen MO, Laufer EM, Winkens MH, Wildberger JE, et al. High-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfort. PLoS One 2012; 7: e35059. pmid:22558116
- 23. Voskoboev NV, Larson TS, Rule AD, Lieske JC. Importance of cystatin C assay standardization. Clin Chem 2011; 57: 1209–1211. pmid:21666068
- 24. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20–29. pmid:22762315
- 25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832. pmid:2407762
- 26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108. pmid:16458610
- 27.
Galiuto L, Badano L, Fox K, Sicari R, Zamorano JL. The EAE Textbook of Echocardiography: Oxford university press; 2011.
- 28. Wildi K, Gimenez MR, Twerenbold R, Reichlin T, Jaeger C, Heinzelmann A, et al. Misdiagnosis of Myocardial Infarction Related to Limitations of the Current Regulatory Approach to Define Clinical Decision Values for Cardiac Troponin. Circulation 2015; 131: 2032–2040. pmid:25948541
- 29. Irfan A, Twerenbold R, Reiter M, Reichlin T, Stelzig C, Freese M, et al. Determinants of high-sensitivity troponin T among patients with a noncardiac cause of chest pain. Am J Med 2012; 125: 491–498 e491. pmid:22482847
- 30. Cardinaels EP, Daamen MA, Bekers O, Ten Kate J, Niens M, van Suijlen JD, et al. Clinical Interpretation of Elevated Concentrations of Cardiac Troponin T, but Not Troponin I, in Nursing Home Residents. J Am Med Dir Assoc 2015.
- 31. Januzzi JL Jr., Bamberg F, Lee H, Truong QA, Nichols JH, Karakas M, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010; 121: 1227–1234. pmid:20194879
- 32. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–2512. pmid:21139111
- 33. Ziebig R, Lun A, Hocher B, Priem F, Altermann C, Asmus G, et al. Renal elimination of troponin T and troponin I. Clin Chem 2003; 49: 1191–1193. pmid:12816921
- 34. Tsutamoto T, Kawahara C, Yamaji M, Nishiyama K, Fujii M, Yamamoto T, et al. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur J Heart Fail 2009; 11: 653–658. pmid:19502379
- 35. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 2011; 124: 136–145. pmid:21709058
- 36. Chenevier-Gobeaux C, Meune C, Freund Y, Wahbi K, Claessens YE, Doumenc B, et al. Influence of age and renal function on high-sensitivity cardiac troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction. Am J Cardiol 2013; 111: 1701–1707. pmid:23540652
- 37. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361: 2538–2547. pmid:19940289
- 38. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 2012; 33: 2272–2281. pmid:22740385
- 39. Hassan HC, Howlin K, Jefferys A, Spicer ST, Aravindan AN, Suryanarayanan G, et al. High-sensitivity troponin as a predictor of cardiac events and mortality in the stable dialysis population. Clin Chem 2014; 60: 389–398. pmid:24185551
- 40. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169. pmid:14581387
- 41. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004; Nov: S11–5. pmid:15485401